Topics

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

2019-07-31 14:47:29 | BioPortfolio

Summary

To assess the primary effects and safety of camrelizumab (SHR-1210) plus apatinib for downstaging/bridging of HCC before liver transplantation.

Description

HCC patients waiting for liver transplantation will be screened and enrolled according to the inclusion criteria. After screening and enrollment, patients will be administrated camrelizumab 200mg q2w iv and apatinib 250mg qd po regimen every 4 weeks as a cycle. Each patient will receive camrelizumab treatment for at least 2 cycles and discontinue camrelizumab 5 weeks before liver transplantation. Apatinib will be discontinued 1 week before liver transplantation. Once the tumor progression was detected, the program will be terminated and the appropriate optimal treatment will be given. The objective remission rate (ORR), recurrence-free survival (RFS), overall survival (OS), time to progress (TTP) and any adverse effect during the study will be evaluated in order to assess the primary effects and safety of camrelizumab (SHR-1210) plus apatinib for downstaging/bridging of HCC before liver transplantation.

Study Design

Conditions

Hepatocellular Carcinoma

Intervention

Camrelizumab plus apatinib

Location

The First Affiliated Hospital of Medical School of Zhejiang University
Hangzhou
Zhejiang
China
310003

Status

Recruiting

Source

Zhejiang University

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-07-31T14:47:29-0400

Clinical Trials [1908 Associated Clinical Trials listed on BioPortfolio]

Carbon-Ion Radiotherapy Plus Camrelizumab With or Without Apatinib for Locally Recurrent Nasopharyngeal Carcinoma

The purpose of this trial is to examine the role of camrezlizumab with or without apatinib in addition to carbon-ion radiotherapy (CIRT) for patients with locally recurrent nasopharyngeal ...

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification

This study was designed to evaluate the effectiveness and safety of hepatic arterial infusion chemotherapy combined with Apatinib and Camrelizumab (Triplet-combined Therapy) for C-staged H...

Camrelizumab Combined With Apatinib for Recurrent Resistant GTN: a Phase 2 Single-arm Prospective Study

This study is intend to improve the progression free survival in treatment of camrelizumab combined with apatinib in platinum-resistant recurrent patients.

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

The study is being conducted to evaluate the efficacy, safety and tolerability of chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery) or adjuvant (...

Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. It is lack of effective drugs for systemic treatment of HCC. Currently, Sorafenib is the only choice...

PubMed Articles [3380 Associated PubMed Articles listed on BioPortfolio]

Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib.

Efficacy of apatinib in advanced hepatocellular carcinoma with lung metastasis: a retrospective, multicenter study.

Lung is the most common extrahepatic metastatic site for patients with advanced hepatocellular carcinoma (HCC) and has a worse prognosis than intrahepatic metastasis. Apatinib is a receptor tyrosine k...

Effectiveness and Safety of Combination Therapy of Transarterial Chemoembolization and Apatinib for Unresectable Hepatocellular Carcinoma in the Chinese Population: A Meta-Analysis.

The combination of transarterial chemoembolization (TACE) and apatinib has been used in the treatment of intermediate or advanced hepatocellular carcinoma (HCC). However, its effectiveness and safety ...

Correction to: Camrelizumab: First Global Approval.

Page 1355, Abstract, Inline table 'Camrelizumab (AiRuiKa™): Key Points', and Introduction.

ATGL promotes the proliferation of hepatocellular carcinoma cells via the p-AKT signaling pathway.

Abnormal metabolism, including abnormal lipid metabolism, is a hallmark of cancer cells. Some studies have demonstrated that the lipogenic pathway might promote the development of hepatocellular carci...

Medical and Biotech [MESH] Definitions

An ORTHOHEPADNAVIRUS causing chronic liver disease and hepatocellular carcinoma in woodchucks. It closely resembles the human hepatitis B virus.

The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum.

The first alpha-globulins to appear in mammalian sera during development of the embryo and the dominant serum proteins in early embryonic life. They reappear in the adult serum during certain pathologic states, primarily hepatocellular carcinoma. They may also be elevated in the amniotic fluid and maternal serum during pregnancy in ANENCEPHALY.

A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.

The founding member of the EPH FAMILY RECEPTORS. It was first cloned from an erythropoietin-producing human hepatocellular carcinoma cell line and is highly conserved among many mammalian species. Overproduction of the EphA1 receptor is associated with tumors and tumor cells of epithelial origin. It is also expressed at high levels in LIVER; LUNG; and KIDNEY; which is in contrast to many other members of the Eph receptor that are found primarily in tissues of the nervous system.

More From BioPortfolio on "Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant"

Quick Search

Searches Linking to this Trial